Revolutionizing Pharma: Unlocking the Power of a Global Federated Data Network
3 minute read
Lifebit
11 September 2024
The pharmaceutical industry is at a turning point as the scale of biomedical data offers unprecedented opportunities for scientific and medical discoveries. However, this also introduces significant challenges. As personal health, medical, and biomedical data continues to grow at an exponential rate, pharmaceutical companies are finding challenges in discovering appropriate datasets for research and development, and there remain problems in efficiently managing, storing, and accessing these highly sensitive data.
Lifebit’s global federated data solutions, including its deep and diverse Global Data Network, provide the opportunity to revolutionize how the pharma industry approaches data discovery, access, and its effective use for drug discovery and precision medicine.
The Data Challenges For Pharma
The pharmaceutical industry is inundated with vast amounts of biomedical data. From clinical trial results to patient records and genomic data, the volume of information is increasing at an exponential rate. However, this data often resides in silos, scattered across various institutions and geographies, making it difficult to discover, access, and integrate for analysis. Moreover, the sensitive nature of this data creates significant security and privacy requirements, further complicating its use in research and development.
The result is slow, expensive, and inefficient drug development processes. In fact, since the 1950s, R&D efficiency has declined, with an 80-fold drop in drug productivity and the cost to develop new drugs doubling every 9 years. The future of pharmaceutical drug development can be unlocked by a significant increase in efficient access to population-level standardized clinical and multi-omic data.
Introduction to Lifebit’s Global Data Network
Lifebit’s vision is to create a world where data is no longer an obstacle to curing diseases but a catalyst for breakthroughs in medicine. Lifebit’s mission is to make biomedical data accessible to all and is committed to breaking down the barriers that have traditionally hindered research and innovation.
Lifebit has established the world’s largest federated data network, with over 150 million patient datasets, representing over 200 health conditions. Uniquely, these data cover disease areas posing the greatest threats to human health, including cancer, cardiovascular, respiratory, neurological, diabetes, and rare diseases.
This data network transcends the boundaries of multiple institutions and nations, providing researchers with access to diverse, high-quality datasets from around the world, providing enormous value for precision medicine and drug development where the ability to access and analyze such data can significantly accelerate the pace of innovation.
Lifebit’s patented technology enables federated access and analysis of data across its expansive data network to advance precision medicine. Lifebit’s federated data platform allows data to remain securely in its original location while enabling researchers to perform analyses remotely. This not only protects data privacy, but also ensures compliance with stringent data protection regulations.
Key Features of the Global Data Network
Advanced Data Management
Lifebit is at the forefront of revolutionizing data management with its federated data platform, which allows users to seamlessly view, search, track, and assess all data in one place. Lifebit’s federated data technology combined with its Global Data Network, enables pharma companies with securely access to vast amounts of data without the need to move or replicate sensitive information.
Real-World Data
Real-World Data (RWD) is becoming increasingly important in drug discovery and development. RWD includes information collected from routine clinical care, such as electronic health records (EHR) and insurance claims data, providing a more comprehensive view of patient outcomes. Lifebit’s Global Data Network facilitates access to RWD, allowing researchers to gain insights that might not be apparent in controlled clinical trials. This can lead to more effective treatments and a faster time to market for new drugs.
Accelerating Drug Discovery with AI and ML
Artificial intelligence (AI) and machine learning (ML) are transforming the pharmaceutical industry by enabling faster, more accurate data analysis. Lifebit integrates AI and ML into its platform to help researchers identify patterns, predict outcomes, and make data-driven decisions more efficiently. The ability to quickly analyze large datasets can lead to the discovery of new biomarkers and the development of targeted therapies.
The Future of Pharma with Federated Data Solutions
Scaling Innovation Across the Industry
As the pharmaceutical industry continues to evolve, the need for innovative data solutions will only grow. Lifebit’s federated data solutions and network are uniquely positioned to meet this need, providing a scalable solution that can support the industry’s future growth. By enabling secure, efficient data sharing and analysis, Lifebit is helping to unlock new possibilities in drug discovery and precision medicine.
Conclusion
Lifebit’s Global Data Network is revolutionizing the pharmaceutical industry by accelerating drug discovery and enabling the development of precision medicine. Through innovative technologies like federated data access and AI-driven analysis, Lifebit is paving the way for a future where data is no longer a barrier to medical breakthroughs but a powerful tool for innovation. As the industry continues to evolve, Lifebit’s commitment to making biomedical data accessible and secure will be crucial in driving the next generation of medical advancements.
About Lifebit
Lifebit is a global leader in precision medicine data and software, empowering organizations across the world to transform how they securely and safely leverage sensitive biomedical data. We are committed to solving the most challenging problems in precision medicine, genomics and healthcare with a mission to create a world where access to biomedical data will never again be an obstacle to curing diseases.
Lifebit's federated technology provides secure access to deep, diverse datasets, including oncology data, from over 100 million patients. Researchers worldwide can securely connect and analyze valuable real-world, clinical, and genomic data in a compliant manner.
.webp)
